Back to discover
Disease

Aphasia

Late-stage therapeutic developmentEmerging research
MeSHAphasia
2
Publications
13
Clinical trials
2023
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • 3 clinical trials expected to report results, the earliest in Q3 2026.
Upcoming Milestones
Major developments
Upcoming trial readoutHigh impact
A Phase 2a Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients With Primary Progressive Aphasia (PPA)
Results expected Q3 20262026-07-06
Upcoming trial readoutImportant
Longitudinal Multi-Modality Imaging in Progressive Apraxia of Speech
Results expected Q2 20282025-11-12
Clinical Milestones5View
Results expected 3
Recently completed 2
Activity timeline5

Clinical trials

12 sponsors · 2 new · 0 completed in the last 12 months (net +2)

The current development programme across all trial phases.

Clinical programme
13
All trials
6
Active
6
Late-stage
6
Completed
Late-stage studies

Longitudinal Multi-Modality Imaging in Progressive Apraxia of Speech

Phase 4 · Recruiting · Mayo Clinic

Effects of Combining Donepezil, Intensive Language Rehabilitation and Transcranial Direct Current Stimulation on Language Recovery and Brain Reorganization in Chronic Post-stroke Aphasia

Phase 3 · Completed · University of Malaga

Augmenting Language Therapy for Aphasia: A Randomized Double-Blind Placebo-Controlled Trial of Levodopa in Combination With Speech-Language Therapy

Phase 2/3 · Completed · Shirley Ryan AbilityLab

Dopaminergic Enhancement of Learning and Memory (LL_001, Project on Aphasia)

Phase 4 · Completed · University Hospital Muenster

Treatment With Donepezil of Chronic Aphasia and Sensorimotor Deficits Associated to Cerebrovascular Accidents: a Double-Blind,Placebo-Controlled, Randomized Parallel Trial.

Phase 4 · Completed · Gabinete Berthier y Martínez

A 24-Week Pilot, Double-Blind, Randomized, Parallel, Placebo-Controlled Study of Memantine and Constraint-Induced Language Therapy in Chronic Poststroke Aphasia:Correlation With Cognitive Evoked Potentials During Recovery.

Phase 4 · Completed · Gabinete Berthier y Martínez
Recently completed

Tau PET Imaging in Atypical Dementias

Phase 1 · Completed · University of Chicago

Effects of Combining Donepezil, Intensive Language Rehabilitation and Transcranial Direct Current Stimulation on Language Recovery and Brain Reorganization in Chronic Post-stroke Aphasia

Phase 3 · Completed · University of Malaga

Augmenting Language Therapy for Aphasia: A Randomized Double-Blind Placebo-Controlled Trial of Levodopa in Combination With Speech-Language Therapy

Phase 2/3 · Completed · Shirley Ryan AbilityLab

A 24-Week Pilot, Double-Blind, Randomized, Parallel, Placebo-Controlled Study of Memantine and Constraint-Induced Language Therapy in Chronic Poststroke Aphasia:Correlation With Cognitive Evoked Potentials During Recovery.

Phase 4 · Completed · Gabinete Berthier y Martínez

Dopaminergic Enhancement of Learning and Memory (LL_001, Project on Aphasia)

Phase 4 · Completed · University Hospital Muenster

Treatment With Donepezil of Chronic Aphasia and Sensorimotor Deficits Associated to Cerebrovascular Accidents: a Double-Blind,Placebo-Controlled, Randomized Parallel Trial.

Phase 4 · Completed · Gabinete Berthier y Martínez

Research activity

2 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Most influential

Speech and language markers of neurodegeneration: a call for global equity.

Brain : a journal of neurology · 2023 · 54 cites

Language impairments in people with autoimmune neurological diseases: A scoping review.

Journal of communication disorders · 2023 · 4 cites
Recent publications

Speech and language markers of neurodegeneration: a call for global equity.

Brain : a journal of neurology · 2023 · 54 cites

Language impairments in people with autoimmune neurological diseases: A scoping review.

Journal of communication disorders · 2023 · 4 cites
Major themes3
  • Aphasia2
  • Alzheimer Disease1
  • Language Development Disorders1
Leading journals2
  • Brain : a journal of neurology1
  • Journal of communication disorders1
Leading researchers8
  • Blasi DE1
  • de Kok D1
  • de Leon J1
  • García AM1
  • Gorno-Tempini ML1
  • Llufriu S1
  • Rofes A1
  • Rook J1
Affiliations (unnormalised)6
  • Center for Language and Cognition1
  • Center of Neuroimmunology1
  • Cognitive Neuroscience Center1
  • Global Brain Health Institute1
  • Harvard University1
  • Latin American Brain Health (BrainLat) Institute1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

A cognitive disorder marked by an impaired ability to comprehend or express language in its written or spoken form. This condition is caused by diseases which affect the language areas of the dominant hemisphere. Clinical features are used to classify the various subtypes of this condition. General categories include receptive, expressive, and mixed forms of aphasia.

Identifiers
MeSHAphasia
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.